BAYRY Bayer Aktiengesellschaft (PK)

By Colin Kellaher

Bayer AG (BAYN.XE) on Monday said it filed a supplemental new-drug application with the U.S. Food and Drug Administration seeking to extend the approved duration of its Mirena intrauterine device to six years.

The Leverkusen, Germany, chemical-and-pharmaceutical company said the request is based on results from a phase 3 extension trial evaluating the efficacy and safety of the contraceptive.

Mirena, which in 2000 became the first hormonal intrauterine device cleared for use in the U.S., is currently approved to prevent pregnancy for up to five years.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 21, 2019 10:58 ET (14:58 GMT)

Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Aug 2024 to Sep 2024

Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Sep 2023 to Sep 2024